| |
|
Research and Development is the cornerstone of Valeant's vision and commitment to delivering innovative
treatments to those whose lives have been affected by disease in every part of the world. We are pleased
with our progress to date in growing our base business and developing our pipeline. To continue growing
our business at average or better than industry average rates, we intend to maintain a focus on Life
Cycle Management for products in our portfolio as well as pursue new opportunities. To this end, we have
developed a comprehensive portfolio management strategy and have laid out a plan for the acquisition of
products in multiple markets around the world with a focus on early-stage clinical candidates. We
believe this strategy provides a balanced approach to growth by increasing the number of new product
offerings in all of our markets, and limiting development risk through the pursuit of a balanced
portfolio. This strategy will allow us to broaden our pipeline and pursue near-term growth prospects in
our three therapeutic franchises in neurology, infectious disease, and dermatology.
Our research and development staff are passionate about their work, and through their dedication and
performance, we accelerated our pace of delivering medicines that make a difference to millions of
people. With the recent launches of Cesamet® and Zelapar® we have demonstrated our ability to bring
potential treatments through development and into the hands of the physicians and patients who need
them.
The development products discussed in the research and development section have not been found by the
U.S. Food and Drug Administration (or other regulatory bodies abroad) to be safe or effective for
treating any disease or illness. Until such time as products are approved by the FDA (or appropriate
regulatory agency in countries) they may not be promoted or sold. |
|
| |
